Lake Street Sticks to Its Buy Rating for TELA Bio (TELA)
TELA Bio(TELA.US) 10% Shareholder Sells US$2.02 Million in Common Stock
$TELA Bio(TELA.US)$ 10% Shareholder ORBIMED ADVISORS LLC sold 428.3K shares of common stock on Jun 28, Jul 1, 2, 2024 at an average price of $4.72 for a total value of $2.02 million. This transaction
Form 144 | TELA Bio(TELA.US) Insider Proposes to Sell 2.2 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 28, $TELA Bio(TELA.US)$ Insider OrbiMed Private Investments IV, LP intends to sell 428.39K shares of its common stock on Jun 28, with a total market value of approximately
Express News | Tela Bio, board of directors increases the number of members to seven.
Express News | TELA Bio Inc - Board Increased Size of Board to Seven Members
Lake Street Maintains TELA Bio(TELA.US) With Buy Rating, Maintains Target Price $14
Lake Street analyst Frank Takkinen maintains $TELA Bio(TELA.US)$ with a buy rating, and maintains the target price at $14.According to TipRanks data, the analyst has a success rate of 34.2% and a tota
Express News | TELA Bio Appoints Jeffrey Blizard to Its Board of Directors
Analysts Are Bullish on Top Healthcare Stocks: TELA Bio (TELA), Rezolute (RZLT)
Analysts Offer Insights on Healthcare Companies: Evogene (EVGN), TELA Bio (TELA) and InfuSystem Holdings, Inc. (INFU)
Press Release: TELA Bio Appoints Greg Firestone as Chief Commercial Officer
TELA Bio Appoints Greg Firestone as Chief Commercial Officer MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on pro
TELA Bio, Inc. (NASDAQ:TELA) Q1 2024 Earnings Call Transcript
TELA Bio First Quarter 2024 Earnings: US$0.23 Loss per Share (Vs US$0.63 Loss in 1Q 2023)
TELA Bio | 10-Q: Quarterly report
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions,
TELA Bio Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Revenue Results and Raised Its FY24 Revenue Guidance.
TELA Bio Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Revenue Results and Raised Its FY24 Revenue Guidance.
TELA Bio Price Target Cut to $10.00/Share From $12.00 by Piper Sandler
TELA Bio Price Target Cut to $10.00/Share From $12.00 by Piper Sandler
Piper Sandler Reiterates Overweight on TELA Bio, Lowers Price Target to $10
Piper Sandler analyst Matt O'Brien reiterates TELA Bio with a Overweight and lowers the price target from $12 to $10.
TELA Bio Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 97.63% Piper Sandler $12 → $10 Reiterates Overweight → Overweight 03/22/2024 196.44% JMP Securi
TELA Bio's Robust Growth and Promising Outlook Merit Bullish Stance
TELA Bio (TELA) Gets a Buy From Piper Sandler